Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Eagle Pharmaceuticals, Inc.

Market Cap 6.79Cr 5.87Cr 5.41Cr 5.06Cr 9.48Cr 645.6Cr 9.63Cr 64Cr 25Cr 314.24Cr 25Cr 25Cr 1.09TCr P/E Ratio 2021
-77x
P/E Ratio 2022 10.7x
Enterprise Value 7.81Cr 6.75Cr 6.22Cr 5.82Cr 11Cr 742.43Cr 11Cr 73Cr 29Cr 361.37Cr 29Cr 29Cr 1.25TCr EV / Sales 2021
3.44x
EV / Sales 2022 1.23x
Free-Float
74.04%
Yield 2021 *
-
Yield 2022 -
1 day-1.64%
Current month+4.35%
1 month+60.00%
3 months+75.90%
6 months+9.09%
Current year-14.29%
1 week 0.03
Extreme 0.0302
0.7
1 month 0
Extreme 0.0014
0.7
Current year 0
Extreme 0.0011
0.85
1 year 0
Extreme 0.0011
3.87
3 years 0
Extreme 0.0011
23.52
5 years 0
Extreme 0.0011
58.25
10 years 0
Extreme 0.0011
97.15
Manager TitleAgeSince
Chief Executive Officer 63 27/11/2023
Director of Finance/CFO 52 11/11/2024
Corporate Officer/Principal - 18/07/2022
Director TitleAgeSince
Director/Board Member 83 01/03/2007
Chairman 63 29/06/2016
Director/Board Member 65 01/07/2016
Date Insider Type Main position Quantity % Market Cap.
28/24/28Tax 2,119 0.0163%
27/24/27Free 16,104 0.1240%
27/24/27Free

Chief Financial Officer

5,389 0.0415%
Change 5-day change 1-year change 3-year change Capi.($)
-1.64%0.00%-75.00%-96.79% 78.14L
-1.42%-1.44%+45.70%+8.24% 29TCr
-1.59%-2.63%+16.07%-20.92% 6.71TCr
-1.74%-2.84%+28.75%+105.32% 824.36Cr
-1.15%+4.87%-3.58%-12.17% 784.46Cr
-0.68%-0.23%-2.66%+8.52% 454.14Cr
+1.05%-0.39%-27.51%+33.10% 379.78Cr
+2.01%+10.19%-14.95%+8.11% 334.87Cr
-2.50%-0.76%+38.65%+31.12% 257.75Cr
+3.11%+1.30%+5.67%-22.84% 197.64Cr
Average -0.45%+2.55%+1.11%+4.17% 3.93TCr
Weighted average by Cap. -1.37%-1.24%+37.28%+5.13%

Financials

2021 2022
Net sales 17Cr 15Cr 14Cr 13Cr 24Cr 1.63TCr 24Cr 161.22Cr 63Cr 793.65Cr 64Cr 63Cr 2.75TCr 32Cr 27Cr 25Cr 24Cr 44Cr 3.01TCr 45Cr 297.54Cr 116.01Cr 1.46TCr 118.82Cr 116.29Cr 5.07TCr
Net income -86.27L -74.51L -68.66L -64.27L -1.2Cr -82Cr -1.22Cr -8.11Cr -3.16Cr -40Cr -3.24Cr -3.17Cr -138.2Cr 3.56Cr 3.08Cr 2.84Cr 2.66Cr 4.98Cr 338.78Cr 5.05Cr 33Cr 13Cr 164.9Cr 13Cr 13Cr 570.95Cr
Net Debt -6.78Cr -5.86Cr -5.4Cr -5.05Cr -9.47Cr -644.82Cr -9.62Cr -64Cr -25Cr -313.86Cr -25Cr -25Cr -1.09TCr 1.02Cr 87.99L 81.08L 75.89L 1.42Cr 97Cr 1.44Cr 9.57Cr 3.73Cr 47Cr 3.82Cr 3.74Cr 163.19Cr
Logo Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals, Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial specializations. The Company is focused on developing medicines that result in improvements in patients' lives. The Company's commercialized products include PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO through its wholly owned subsidiary Acacia Pharma Inc. The Company’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Its pipeline includes ENA-001 and EA-114. EA-114 is a novel and proprietary formulation of fulvestrant being developed for hormone-receptor-positive (HR+) metastatic breast cancer. ENA-001 is an investigational new chemical entity being developed by the Company’s partner, Enalare, as an agnostic respiratory stimulant for multiple patient populations experiencing respiratory depression.
Employees
134
Date Price Change Volume
12/26/12 0.6000 $ -1.64% 9,360
10/26/10 0.6100 $ +1.67% 982
05/26/05 0.6000 $ +14.29% 300
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. EGRX Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!